Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and...
October 23, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the...
October 16, 2025 09:00 ET | Source: Scienture Holdings, Inc.

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions,...
October 08, 2025 09:00 ET | Source: Scienture Holdings, Inc.

SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet

COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...
October 01, 2025 09:00 ET | Source: Scienture Holdings, Inc.

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with...
September 16, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK,...
August 14, 2025 09:00 ET | Source: Scienture Holdings, Inc.

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies...
August 13, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced...
July 24, 2025 17:12 ET | Source: Scienture Holdings, Inc.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on...
July 16, 2025 08:15 ET | Source: Scienture Holdings, Inc.

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on...